Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2007;101:734-741
Published online before print August 2, 2007, doi: 10.1161/CIRCRESAHA.107.153023
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/7/734    most recent
CIRCRESAHA.107.153023v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ito, T.
Right arrow Articles by Ozawa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ito, T.
Right arrow Articles by Ozawa, K.
Related Collections
Right arrow Remodeling
Right arrow Animal models of human disease
Right arrow Smooth muscle proliferation and differentiation
Right arrow Pulmonary circulation and disease
(Circulation Research. 2007;101:734.)
© 2007 American Heart Association, Inc.


Integrative Physiology

Interleukin-10 Expression Mediated by an Adeno-Associated Virus Vector Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats

Takayuki Ito, Takashi Okada, Hiroshi Miyashita, Tatsuya Nomoto, Mutsuko Nonaka-Sarukawa, Ryosuke Uchibori, Yoshikazu Maeda, Masashi Urabe, Hiroaki Mizukami, Akihiro Kume, Masafumi Takahashi, Uichi Ikeda, Kazuyuki Shimada, Keiya Ozawa

From the Division of Genetic Therapeutics (T.I., T.N., M.N.-S., M.U., H.M., A.K., K.O., R.U.), the Division of Cardiovascular Medicine (T.I., H.M., M.N.-S., K.S., Y.M.), Jichi Medical University, Japan; the Department of Molecular Therapy (T.O.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan; and the Department of Organ Regeneration (M.T., U.I.), Shinshu University Graduate School of Medicine, Japan.

Correspondence to Takayuki Ito, MD, PhD, Division of Genetic Therapeutics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan. E-mail titou{at}jichi.ac.jp

Pulmonary arterial hypertension (PAH) is a fatal disease associated with inflammation and pathological remodeling of the pulmonary artery (PA). Interleukin (IL)-10 is a pleiotropic antiinflammatory cytokine with vasculoprotective properties. Here, we report the preventive effects of IL-10 on monocrotaline-induced PAH. Three-week-old Wistar rats were intramuscularly injected with an adeno-associated virus serotype 1 vector expressing IL-10, followed by monocrotaline injection at 7 weeks old. IL-10 transduction significantly improved survival rates of the PAH rats 8 weeks after monocrotaline administration compared with control gene transduction (75% versus 0%, P<0.01). IL-10 also significantly reduced mean PA pressure (22.8±1.5 versus 29.7±2.8 mm Hg, P<0.05), a weight ratio of right ventricle to left ventricle plus septum (0.35±0.04 versus 0.42±0.05, P<0.05), and percent medial thickness of the PA (12.9±0.3% versus 21.4±0.4%, P<0.01) compared with controls. IL-10 significantly reduced macrophage infiltration and vascular cell proliferation in the remodeled PA in vivo. It also significantly decreased the lung levels of transforming growth factor-ß1 and IL-6, which are indicative of PA remodeling. In addition, IL-10 increased the lung level of heme oxygenase-1, which strongly prevents PA remodeling. In vitro analysis revealed that IL-10 significantly inhibited excessive proliferation of cultured human PA smooth muscle cells treated with transforming growth factor-ß1 or the heme oxygenase inhibitor tin protoporphyrin IX. Thus, IL-10 prevented the development of monocrotaline-induced PAH, and these results provide new insights into the molecular mechanisms of human PAH.


Key Words: pulmonary hypertension • interleukins • gene therapy • inflammation • vascular smooth muscle cell proliferation




This article has been cited by other articles:


Home page
HypertensionHome page
Y. Wang and Z. Sun
Klotho Gene Delivery Prevents the Progression of Spontaneous Hypertension and Renal Damage
Hypertension, October 1, 2009; 54(4): 810 - 817.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. L. Burke, M. G. Frid, C. L. Kunrath, V. Karoor, A. Anwar, B. D. Wagner, D. Strassheim, and K. R. Stenmark
Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment
Am J Physiol Lung Cell Mol Physiol, August 1, 2009; 297(2): L238 - L250.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. K. Idriss, A. D. Blann, and G. Y.H. Lip
Hemoxygenase-1 in Cardiovascular Disease
J. Am. Coll. Cardiol., September 16, 2008; 52(12): 971 - 978.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
N. G. Abraham and A. Kappas
Pharmacological and Clinical Aspects of Heme Oxygenase
Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
E. Daley, C. Emson, C. Guignabert, R. de Waal Malefyt, J. Louten, V. P. Kurup, C. Hogaboam, L. Taraseviciene-Stewart, N. F. Voelkel, M. Rabinovitch, et al.
Pulmonary arterial remodeling induced by a Th2 immune response
J. Exp. Med., February 18, 2008; 205(2): 361 - 372.
[Abstract] [Full Text] [PDF]